Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.9%

4 terminated out of 137 trials

Success Rate

92.2%

+5.7% vs benchmark

Late-Stage Pipeline

10%

14 trials in Phase 3/4

Results Transparency

11%

5 of 47 completed with results

Key Signals

5 with results92% success

Data Visualizations

Phase Distribution

68Total
Not Applicable (43)
P 1 (4)
P 2 (7)
P 3 (3)
P 4 (11)

Trial Status

Completed47
Unknown39
Recruiting27
Not Yet Recruiting10
Terminated4
Active Not Recruiting4

Trial Success Rate

92.2%

Benchmark: 86.5%

Based on 47 completed trials

Clinical Trials (137)

Showing 20 of 20 trials
NCT07305363Phase 2Not Yet RecruitingPrimary

Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

NCT06257407RecruitingPrimary

Perioperative Hemostasis Management in Liver Transplantation

NCT04901169Phase 2Active Not RecruitingPrimary

Angiotensin II in Liver Transplantation

NCT05042505Not ApplicableCompleted

Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

NCT06879106Not ApplicableCompletedPrimary

Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation

NCT07409532CompletedPrimary

Intraoperative Assessment of Renal Tissue Oxygenation Using NIRS

NCT07362745Completed

Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury

NCT05241847Not ApplicableCompletedPrimary

Starzl Network Patient Reported Outcomes

NCT06169592Recruiting

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

NCT06958796Phase 4Recruiting

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT07169643Phase 3RecruitingPrimary

Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

NCT06816628Not ApplicableCompletedPrimary

Effects of Comedy Therapy on Pain and Comfort Levels in Liver Transplant Recipients

NCT04613921Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT05031026Phase 4Active Not RecruitingPrimary

Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

NCT06919588Not ApplicableCompletedPrimary

Effects of Comedy Therapy on Anxiety and Vital Signs in Transplant Recipients

NCT04246970Not ApplicableEnrolling By InvitationPrimary

Prehabilitation and Posttransplant Training Program in Liver Transplantation

NCT04592744Phase 4Enrolling By Invitation

Angiotensin 2 for AKI After OLT

NCT05146336Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT05242315Phase 4RecruitingPrimary

Extended-Release Tacrolimus Following Liver Transplantation

NCT07132697Not ApplicableNot Yet RecruitingPrimary

The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant

Scroll to load more

Research Network

Activity Timeline